Pharma & Biotech News , from our Global Correspondents
Refine Search
Pharmaceutical
In what could be construed to be India's quest for pharmaceutical supremacy, a clarion call has been made for the country to set its indigenous standards. 25 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Pharmaceutical
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
Generics
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
Pharmaceutical
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
Biotechnology
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
Generics
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Biotechnology
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
Generics
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Pharmaceutical
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
Generics
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Pharmaceutical
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Pharmaceutical
The Russia government has updated the existing draft strategy for the development of the domestic pharmaceutical industry - Pharma-2030, reports The Pharma Letter’s local correspondent. 20 April 2023
Biotechnology
Biotech investors are cautiously optimistic about opportunities in China in 2023, and they are looking for novel or value-added assets only, said investors at the CMAC conference held in Suzhou in earlier this month. 19 April 2023
Biotechnology
For EC Awareness month, The Pharma Letter examines the treatment landscape of esophageal cancer (EC), a rare but deadly malignancy that is the sixth most common cause of cancer-related deaths in the world.1 18 April 2023
Generics
Several international investors and fund managers have expressed an interest in investing in the Indian pharmaceutical and biotechnology sectors, underlining the need to establish a platform to facilitate the transition of global capital flows into the domestic economy. 14 April 2023
Biosimilars
A lot of topics were discussed at the 2023 China innovative medicine (device) medical conference (CMAC) held in Suzhou on April 7. Among them were real world studies, medical affairs and how to use AI to speed up discoveries. But one most talked about was the challenges for Chinese biotechs to go global. 13 April 2023
Pharmaceutical
US pharma major Eli Lilly has become the second American drugmaker, after Bristol-Myers Squibb, that has decided to exit the Russian market, reports The Pharma Letter’s local correspondent. 11 April 2023
Generics
The Russian government plans to take additional measures to further increase the share of domestic drugs in the local market, as pressure from the West on the country and its pharmaceutical sector is growing. 7 April 2023
Pharmaceutical
Improving the availability of innovative medicines in Latin America is a key priority for the pharmaceutical industry, policymakers, and patients. 31 March 2023
Generics
The expiration of the patent for palbociclib, a leading anti-breast cancer drug, in India has opened up new opportunities for generic versions of the drug. The Indian government highlighted this development in Parliament and intensely discussed the endless possibilities that could arise from the availability of generic palbociclib and other similar generic oncology drugs, reports The Pharma Letter’s India correspondent. 30 March 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of the current year. 29 March 2023
Generics
Russia will allow domestic drugmakers to develop generics of original foreign drugs under patent protection only in case of exodus of their producers from the Russian market. 29 March 2023
Pharmaceutical
The niche of Western pharmaceutical companies that have suspended their clinical trials in Russia may be replaced by their competitors from the Asia Pacific as well as Middle East region, according to recent statements by some leading Russian analysts in the field of pharmaceutical business and some local media, reports The Pharma Letter’s correspondent. 22 March 2023
Biotechnology
Research-based Egyptian pharma company Gennecs Pharmaceuticals, part of the Gennecs group, belongs to the to El Daba Holding Group, a trading conglomerate serving Egypt and the countries of the Gulf Cooperation Council that partners with local and international investors. 20 March 2023
Pharmaceutical
Russia may face a shortage of rare disease drug Cuprenil (penicillamine), according to government procurement statistics data and the statistics of the commercial retail, reports The Pharma Letter’s local correspondent. 14 March 2023
Pharmaceutical
Sales of Russian drugs grew in 2022 due to an increase of advertising budgets and a decline of the share of foreign drugs, reports The Pharma Letter’s local correspondent. 14 March 2023
Pharmaceutical
In June 2021, the US Food and Drug Administration (FDA) approved Novo Nordisk’s (NOV: N) type 2 diabetes drug Wegovy (semaglutide) injection for chronic weight management in overweight or obese adults with at least one weight-related condition.1 This is just one example of the potential for existing drugs to offer new uses – also known as drug repurposing. 14 March 2023
Pharmaceutical
March is Wilson’s Disease Awareness Month – an opportunity to raise awareness and explore progress within the management and treatment of this rare condition. 13 March 2023
Pharmaceutical
Keen to accelerate vaccine drug development and approvals in India, an expert committee of India's Central Drugs Standard Control Organization (CDSCO) met recently to review the research efforts of pharmaceutical companies. 10 March 2023
Generics
Zeta Pharma is a fast-growing branded generic pharmaceutical company in the Egyptian market that was established in 2010 and started its production and marketing activities in 2015 on the hepatitis C virus products products Sofocivir, Zetaciver and Sofocivir Plus. 10 March 2023
Biosimilars
The Russian drugmaker R-Pharm is accelerating its expansion in the domestic market this year with the planned investments of 4 billion roubles ($100 million) in the building a new production facility in St Petersburg and the establishment of a large-scale production in the capital city of Moscow. 7 March 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze